Univariate | Multivariate | |||
---|---|---|---|---|
B (95%CI) | P | B (95%CI) | P | |
Age, y | ||||
18–25 | – | |||
26–35 | −8.4 (− 12.4; − 4.5) | < 0.001 | −5.5 (− 9.5; − 1.4) | 0.008+ |
36–45 | − 14.6 (− 19.3; − 9.9) | < 0.001 | − 9.7 (− 14.6; − 4.7) | < 0.001+ |
> 45 | −22.6 (− 28.7; − 16.5) | < 0.001 | − 15.4 (− 22.1; − 8.7) | < 0.001+ |
Sex, Female | 1.7 (− 1.9; 5.2) | 0.36 | – | – |
Baseline characteristics | ||||
Body mass index, kg/m2 | −0.2 (− 0.9; 0.4) | 0.66 | – | – |
Fat mass index, kg/m2 | −0.3 (− 1.2; 0.5) | 0.46 | – | |
Fat free mass index, kg/m2 | −0.2 (− 1.2; 0.8) | 0.72 | – | – |
Hypertension, Yes | 0.01 (− 6; 6) | 0.99 | – | – |
C-reactive protein, mg/L | −0.01 (− 0.1; 0.07) | 0.99 | – | – |
CD4 count, cells/ul | 0.002 (−0.01; 0.02) | 0.83 | – | – |
On tuberculosis treatment, Yes | −1.8 (− 7.5; 3.9) | 0.53 | – | – |
Hepatitis B surface antigen positive, Yes | 4.2 (− 5.3; 13.8) | 0.38 | – | – |
Hepatitis C virus antibody Positive, Yes | 0.5 (−26.2; 27.3) | 0.97 | – | – |
Viral load, log (copies+ 1/mL) | 0.3 (−1.4; 2.1) | 0.68 | – | – |
eGFR, ml/min/1.73 m2 | 0.3 (0.23; 0.38) | < 0.001 | 0.2 (0.1; 0.3) | < 0.001+ |
Six month change | ||||
Change in body mass index, kg/m2 | 0.1 (−1; 1.2) | 0.87 | – | – |
Change in fat mass index, kg/m2 | −0.4 (−1.8; 1) | 0.58 | – | – |
Change in fat free mass index, kg/m2 | 0.8 (−1; 2.6) | 0.37 | – | – |
Change in CD4 count, cells/ul | 0.03 (0.01; 0.05) | < 0.001 | 0.01 (−0.005; 0.02) | 0.18+ |
Viral load > 1000 copies/ml at 6 months, Yes | −15.1 (−23.4; −6.8) | < 0.001 | −9.9 (− 17.2; − 2.5) | 0.009+ |
Antiretroviral treatment | ||||
TDF Treatment | −2.5 (−7; 2) | 0.28 | 0.2 (−3.8; 4.2) | 0.93* |